According to an investigation in the February 1 issue of JAMA, surgery to remove additional tissue (reexcision) is required in almost 1 in 4 women who undergo a partial mastectomy for breast cancer treatment. In addition, there is considerable surgeon and institutional difference in the rate of reexcisions that have ...

A new study reveals substantial differences - by both surgeon and institution - in the rates of follow-up surgeries for women who underwent a partial mastectomy for treatment of breast cancer.

Nearly one in four women who undergo a partial mastectomy for treatment of breast cancer have another surgery to remove additional tissue (reexcision), and there is substantial surgeon and institutional variation in the rate of reexcisions that cannot be explained by patients' clinical characteristics, according to a study in the ...

Grand Rapids, Mich. (January 31, 2012) A new study reveals substantial differences by both surgeon and institution in the rates of follow-up surgeries for women who underwent a partial mastectomy for treatment of breast cancer. Those differences, which cannot be explained by a ...

(Michigan State University) A new study reveals substantial differences -- by both surgeon and institution -- in the rates of follow-up surgeries for women who underwent a partial mastectomy for treatment of breast cancer.Those differences, which cannot be explained by a patient's medical or treatment history, could affect both cancer ...

(Van Andel Research Institute) A new study reveals substantial differences -- by both surgeon and institution -- in the rates of follow-up surgeries for women who underwent a partial mastectomy for treatment of breast cancer.

Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.

Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy growing increasingly popular as a treatment choice for women with early-stage breast cancer, is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole breast irradiation (WBI), according to researchers from ...

Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy growing increasingly popular as a treatment choice for women with early-stage breast cancer, is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole breast irradiation (WBI), according to researchers from ...

New research casts doubt on a popular treatment for breast cancer: A week of radiation to part of the breast instead of longer treatment to all of it.

San Antonio, TX - Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy growing increasingly popular as a treatment choice for women with early-stage breast cancer, is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole breast irradiation (WBI), ...

The 29th International Epilepsy Congress in Rome, Italy (28th August-1st September) 1-4 presented consistent evidence this week, that a combined treatment with Vimpat® (lacosamide) has generally been well tolerated and linked to a sustained reduction in partial onset seizures for up to 8 years. Lacosamide, launched in the E.U. in ...